ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
소화기암 시장 규모는 향후 수년간 급성장이 예상됩니다. 시장 성장의 요인으로는 헬스케어 시스템 강화, 암 치료에 대한 정부의 지원 프로그램, 저침습 치료 기술에 대한 기호 고조 등이 있습니다. 이 기간에 예측되는 주된 시장 동향에는 진단 기술의 진보, 표적 요법과 면역 요법의 획기적 진보, 암 관리에서의 인공지능의 통합, 정밀 의료 연구의 지속적인 진전 등이 있습니다.
표적 요법의 채용이 증가하면서 향후 소화기암 시장의 성장을 가속할 것으로 예측됩니다. 표적 요법은 분자 경로와 유전자 돌연변이에 작용하도록 설계되었습니다. 건강한 세포와 질병 세포를 모두 공격하는 화학 요법과 같은 전통적인 치료와는 달리, 표적 요법은 환자의 병리학상의 특이적인 특징에 초점을 맞춥니다. 표적 요법은 특정 유전자 또는 단백질에 작용하여 정확하고 효과적인 치료를 가능하게 합니다. 이 접근법은 기존의 화학 요법에 비해 부작용이 적고, 보다 좋은 치료 결과를 제공합니다. 2023년 7월, American Society of Gene & Cell Therapy (ASGCT)와 Citeline사에 의하면 제1분기(Q1)말까지 페이즈 II 단계에 있는 유전자 치료는 247건이었으며, 제2분기(Q2)말까지 5% 증가해 260건에 이르렀습니다.
소화기암 시장에서 사업을 전개하는 주요 기업은 환자 생존율을 향상시키고 치료와 관련된 부작용을 최소화하기 위해 단일클론항체 치료 등 첨단 솔루션 개발에 주력하고 있습니다. 단일클론항체 치료는 암세포를 정확하게 식별하여 부착하고 면역계가 암세포를 표적으로 배제하는 것을 보조하도록 실험실에서 제작된 항체를 사용합니다. 예를 들어, 2024년 9월 일본 제약회사인 Astellas Pharma Inc.는 플루오로피리미딘 및 백금 제제를 포함한 화학 요법과 병용하는 VYLOY(졸베툭시맙)를 발표하여 유럽위원회로부터 승인을 받았습니다. 이 약은 클로딘 18.2(CLDN18.2)를 발현하는 절제 불가능 또는 전이성 국소 진행성 HER2 음성 위 또는 위 식도 접합부(GEJ) 선암 성인 환자에 대한 1차 치료제입니다. 이번 승인을 통해 VYLOY는 SPOTLIGHT 및 GLOW 시험의 양호한 임상시험 데이터를 바탕으로 이러한 환자의 약 38%에 존재하는 바이오마커인 CLDN18.2를 표적으로 하는 유럽 연합 최초의 치료제로 인정받았습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 소화기암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 소화기암 시장 : 성장률 분석
세계의 소화기암 시장 실적 : 규모와 성장(2019-2024년)
세계의 소화기암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계 소화기암 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 소화기암 시장 : 암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
대장암
위암
식도암
췌장암
간암
기타 암 유형
세계의 소화기암 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
내시경 검사
생검
분자 진단
화상 진단
기타 진단
세계의 소화기암 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
화학 요법
면역 요법
표적 요법
방사선 치료
수술
기타 치료
세계의 소화기암 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
종양학 센터
연구 기관
진단 실험실
기타 최종 사용자
세계의 소화기암 시장, 대장암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
대장암
직장암
재발성 대장암
전이성 대장암
세계의 소화기암 시장, 위암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
선암암
소화관 간질 종양(GIST)
림프종
카르티노이드 종양
세계의 소화기암 시장, 식도암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
선암암
편평상피암
소세포암
기타 희귀 식도 종양
세계의 소화기암 시장, 췌장암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
외분비 췌장암
내분비(신경내분비) 췌장 종양
전이성 췌장암
절제 가능 또는 절제 불가능한 종양
세계의 소화기암 시장, 간암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
간세포암(HCC)
간내 담관암
간아종
2차성(전이성) 간암
세계의 소화기암 시장, 기타 암 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소장암
항문암
담낭암
소화관 카르티노이드 종양
제7장 지역별/국가별 분석
세계의 소화기암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 소화기암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
소화기암 시장 : 경쟁 구도
소화기암 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca PLC
Novartis AG
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Parexel International Corporation
Ipsen Biopharmaceuticals Inc.
Exelixis Inc.
BeiGene Ltd.
Boehringer Ingelheim International GmbH
Zai Lab Limited
Taiho Pharmaceutical Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
소화기암 시장(2029년) : 새로운 기회를 제공하는 국가
소화기암 시장(2029년) : 새로운 기회를 제공하는 부문
소화기암 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Gastrointestinal (GI) cancer comprises a group of malignancies that affect the digestive organs, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers occur when abnormal cells begin to grow uncontrollably within the gastrointestinal tract. The primary objectives of GI cancer treatment are to remove or manage the cancer, alleviate associated symptoms, and enhance the patient's quality of life.
The major categories of gastrointestinal cancer include colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer, which affects the colon or rectum, is largely influenced by genetic predispositions and lifestyle factors, making it suitable for focused screening and specialized treatment approaches in GI oncology. Diagnosis is conducted using techniques such as endoscopy, biopsy, molecular diagnostics, imaging, and more. Treatment options consist of chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and other modalities. These are utilized across various settings, including hospitals, oncology centers, diagnostic labs, research institutions, and others.
The gastrointestinal cancer market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal cancer market statistics, including the gastrointestinal cancer industry global market size, regional shares, competitors with the gastrointestinal cancer market share, detailed gastrointestinal cancer market segments, market trends, opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. This gastrointestinal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gastrointestinal cancer market size has grown rapidly in recent years. It will grow from $24.09 billion in 2024 to $27.05 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The expansion during the historic period was fueled by the increasing incidence of GI cancers, heightened tobacco and alcohol use, a rising elderly population, unhealthy dietary patterns, and significant progress in cancer diagnostics and treatment methods.
The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $42.45 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by the wider application of biomarker-based therapies, greater public awareness regarding early cancer detection, strengthened healthcare systems, supportive government programs for oncology care, and a rising preference for less invasive treatment techniques. Key market trends projected for this period include advancements in diagnostic technologies, breakthroughs in targeted and immunotherapies, integration of artificial intelligence in cancer management, and continued progress in precision medicine research.
The rising adoption of targeted therapies is expected to propel the growth of the gastrointestinal cancer market going forward. Targeted therapies are treatments that precisely block cancer cell growth by acting on specific molecular targets, reducing harm to normal, healthy cells. These therapies are designed to act on specific molecular pathways or genetic mutations driving a disease, especially in cancer. Unlike traditional treatments like chemotherapy, which attack both healthy and diseased cells, targeted therapies focus on the unique characteristics of a patient's condition. In the case of gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins that control tumor growth, enabling precise and effective treatment. This approach results in better outcomes with fewer side effects compared to conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II by the end of quarter one (Q1) 2023, which rose by 5% to reach 260 by the end of quarter two (Q2). Therefore, the rising adoption of targeted therapies is driving the growth of the gastrointestinal cancer market.
Major companies operating in the gastrointestinal cancer market are focused on developing advanced solutions, such as monoclonal antibody treatment, to improve patient survival rates and minimize treatment-related side effects. Monoclonal antibody treatment involves using laboratory-produced antibodies that precisely identify and attach to cancer cells, assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, which received approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first and only therapy in the European Union targeting CLDN18.2, a biomarker present in about 38% of these patients, based on positive clinical trial data from the SPOTLIGHT and GLOW studies.
In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. With this acquisition, GSK aims to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its capabilities in precision medicine to better address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).
Major players in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, and Taiho Pharmaceutical Co. Ltd.
North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastrointestinal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastrointestinal Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastrointestinal cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastrointestinal cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Cancer Type: Colorectal Cancer; Stomach Cancer; Esophageal Cancer; Pancreatic Cancer; Liver Cancer; Other Cancer Types
2) By Diagnostics: Endoscopy; Biopsy; Molecular Diagnostics; Imaging; Other Diagnostics
3) By Treatment: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery; Other Treatments
4) By End-User: Hospitals; Oncology Centers; Research Institutes; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Colorectal Cancer: Colon Cancer; Rectal Cancer; Recurrent Colorectal Cancer; Metastatic Colorectal Cancer
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastrointestinal Cancer Market Characteristics
3. Gastrointestinal Cancer Market Trends And Strategies
4. Gastrointestinal Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gastrointestinal Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Gastrointestinal Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastrointestinal Cancer Market Growth Rate Analysis
5.4. Global Gastrointestinal Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastrointestinal Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastrointestinal Cancer Total Addressable Market (TAM)
6. Gastrointestinal Cancer Market Segmentation
6.1. Global Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Pancreatic Cancer
Liver Cancer
Other Cancer Types
6.2. Global Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopy
Biopsy
Molecular Diagnostics
Imaging
Other Diagnostics
6.3. Global Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
Other Treatments
6.4. Global Gastrointestinal Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Oncology Centers
Research Institutes
Diagnostic Laboratories
Other End-Users
6.5. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Colorectal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Colon Cancer
Rectal Cancer
Recurrent Colorectal Cancer
Metastatic Colorectal Cancer
6.6. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Stomach Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenocarcinoma
Gastrointestinal Stromal Tumors (GIST)
Lymphoma
Carcinoid Tumors
6.7. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Esophageal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenocarcinoma
Squamous Cell Carcinoma
Small Cell Carcinoma
Other Rare Esophageal Tumors
6.8. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Pancreatic Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exocrine Pancreatic Cancer
Endocrine (Neuroendocrine) Pancreatic Tumors
Metastatic Pancreatic Cancer
Resectable Or Unresectable Tumors
6.9. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatocellular Carcinoma (HCC)
Intrahepatic Cholangiocarcinoma
Hepatoblastoma
Secondary (Metastatic) Liver Cancer
6.10. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Intestine Cancer
Anal Cancer
Gallbladder Cancer
Gastrointestinal Carcinoid Tumors
7. Gastrointestinal Cancer Market Regional And Country Analysis
7.1. Global Gastrointestinal Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastrointestinal Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastrointestinal Cancer Market
8.1. Asia-Pacific Gastrointestinal Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastrointestinal Cancer Market
9.1. China Gastrointestinal Cancer Market Overview
9.2. China Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastrointestinal Cancer Market
10.1. India Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastrointestinal Cancer Market
11.1. Japan Gastrointestinal Cancer Market Overview
11.2. Japan Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastrointestinal Cancer Market
12.1. Australia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastrointestinal Cancer Market
13.1. Indonesia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastrointestinal Cancer Market
14.1. South Korea Gastrointestinal Cancer Market Overview
14.2. South Korea Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastrointestinal Cancer Market
15.1. Western Europe Gastrointestinal Cancer Market Overview
15.2. Western Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastrointestinal Cancer Market
16.1. UK Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastrointestinal Cancer Market
17.1. Germany Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastrointestinal Cancer Market
18.1. France Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastrointestinal Cancer Market
19.1. Italy Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastrointestinal Cancer Market
20.1. Spain Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastrointestinal Cancer Market
21.1. Eastern Europe Gastrointestinal Cancer Market Overview
21.2. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastrointestinal Cancer Market
22.1. Russia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastrointestinal Cancer Market
23.1. North America Gastrointestinal Cancer Market Overview
23.2. North America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastrointestinal Cancer Market
24.1. USA Gastrointestinal Cancer Market Overview
24.2. USA Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastrointestinal Cancer Market
25.1. Canada Gastrointestinal Cancer Market Overview
25.2. Canada Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastrointestinal Cancer Market
26.1. South America Gastrointestinal Cancer Market Overview
26.2. South America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastrointestinal Cancer Market
27.1. Brazil Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastrointestinal Cancer Market
28.1. Middle East Gastrointestinal Cancer Market Overview
28.2. Middle East Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastrointestinal Cancer Market
29.1. Africa Gastrointestinal Cancer Market Overview
29.2. Africa Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastrointestinal Cancer Market Competitive Landscape And Company Profiles
30.1. Gastrointestinal Cancer Market Competitive Landscape
30.2. Gastrointestinal Cancer Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Gastrointestinal Cancer Market Other Major And Innovative Companies
31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca PLC
31.4. Novartis AG
31.5. GlaxoSmithKline plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. Parexel International Corporation
31.10. Ipsen Biopharmaceuticals Inc.
31.11. Exelixis Inc.
31.12. BeiGene Ltd.
31.13. Boehringer Ingelheim International GmbH
31.14. Zai Lab Limited
31.15. Taiho Pharmaceutical Co. Ltd.
32. Global Gastrointestinal Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastrointestinal Cancer Market
34. Recent Developments In The Gastrointestinal Cancer Market
35. Gastrointestinal Cancer Market High Potential Countries, Segments and Strategies
35.1 Gastrointestinal Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastrointestinal Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastrointestinal Cancer Market In 2029 - Growth Strategies
